# Furosemide

```text
DRUG INFORMATION

  ADULT
    - Edema : • Initial dose is 20 mg to 40 mg once given intramuscularly or
      intravenously.
      Source: US FDA label for furosemide (Furosemide), section 'dosage and
      administration', retrieved 2026-08-29
    - If needed, dosage may be increased by 1 mg/kg not sooner than 2 hours after the
      previous dose, until the desired diuretic effect has been obtained.
      Source: US FDA label for furosemide (Furosemide), section 'dosage and
      administration', retrieved 2026-08-29
    - Doses greater than 6 mg/kg body weight are not recommended ( 2.3 ) 2.1 General
      Considerations Inspect Furosemide Injection visually for particulate matter and
      discoloration before administration. 2.2 Recommended Dosage for Adults Edema
      Individualize therapy according to patient response.
      Source: US FDA label for furosemide (Furosemide), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Published reports indicate that premature infants with post conceptual age
      (gestational plus postnatal) less than 31 weeks receiving doses exceeding 1
      mg/kg/24 hours may develop plasma levels which could be associated with potential
      toxic effects including ototoxicity [see Warnings and Precautions ( 5.3 )] .
      Source: US FDA label for furosemide (Furosemide), section 'pediatric use',
      retrieved 2026-08-29
    - If needed, dosage may be increased by 1 mg/kg not sooner than 2 hours after the
      previous dose, until the desired diuretic effect has been obtained.
      Source: US FDA label for furosemide (Furosemide), section 'dosage and
      administration', retrieved 2026-08-29
    - Doses greater than 6 mg/kg body weight are not recommended ( 2.3 ) 2.1 General
      Considerations Inspect Furosemide Injection visually for particulate matter and
      discoloration before administration. 2.2 Recommended Dosage for Adults Edema
      Individualize therapy according to patient response.
      Source: US FDA label for furosemide (Furosemide), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Reports usually indicate that furosemide ototoxicity is associated with rapid
      injection, severe renal impairment, the use of higher than recommended doses,
      hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic
      acid, or other ototoxic drugs.
      Source: US FDA label for furosemide (Furosemide), section 'warnings and cautions',
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for furosemide (Furosemide),
      retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Available data from published observational studies, case reports,
      and postmarketing reports, from decades of use, have not demonstrated a drug-
      associated risk of major birth defects, miscarriage, or other adverse maternal or
      fetal outcomes with furosemide use during pregnancy.
      Source: US FDA label for furosemide (Furosemide), section 'pregnancy', retrieved
      2026-08-29
    - Untreated congestive heart failure and cirrhosis of the liver can lead to adverse
      outcomes for the mother and the fetus (see Clinical Considerations ) .
      Source: US FDA label for furosemide (Furosemide), section 'pregnancy', retrieved
      2026-08-29
    - In animal reproduction studies, furosemide has been shown to cause unexplained
      maternal deaths and abortions in rabbits when administered orally during
      organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area
      (BSA) and oral bioavailability corrections, presumably secondary to volume
      depletion (see Data ) .
      Source: US FDA label for furosemide (Furosemide), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - The results of the mouse study and one of the three rabbit studies also showed an
      increased incidence and severity of hydronephrosis (distention of the renal pelvis
      and, in some cases, of the ureters) in fetuses of treated dams as compared with
      the incidence of fetuses from the control group. 8.2 Lactation Risk Summary The
      presence of furosemide has been reported in human milk.
      Source: US FDA label for furosemide (Furosemide), section 'use in specific
      populations', retrieved 2026-08-29
    - There are no data on the effects on the breastfed infant or the effects on milk
      production.
      Source: US FDA label for furosemide (Furosemide), section 'use in specific
      populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother's clinical need for furosemide and any potential adverse effects
      on the breastfed infant from furosemide or from the underlying maternal condition.
      Source: US FDA label for furosemide (Furosemide), section 'use in specific
      populations', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)